Latest Mesothelioma Clinical Trial Opens at Memorial Sloan Kettering

Memorial Sloan Kettering Cancer Center in New York City has opened its latest clinical trial for patients with pleural mesothelioma, studying the effectiveness of an immunotherapy and chemotherapy combination prior to aggressive surgery. The novel feasibility study will determine if the use of Opdivo (nivolumab) with Alimta (pemetrexed) and either cisplatin or carboplatin — without delaying scheduled surgery — can significantly extend patient survival time. The hope is to duplicate earlier effectiveness of that same combination with other cancers. “It has been tried with promising results,” Memorial Sloan Kettering thoracic surgeon Dr. Prasad Adusumilli told The Mesothelioma Center at Asbestos.com. “Let’s wait and see what we learn here, but perhaps with this, we can prolong survival beyond standard treatment.” Adusumilli Leads Mesothelioma Program Patients selected for the study will undergo two cycles of the Opdivo and chemotherapy combination prior to the extensive pleurectomy and decortication surgery. The initial outcome measure will be the number of patients progressing to surgery within 30 days of the originally planned operation. Failure will be a toxicity-induced delay of surgery for more than 30 days. Either Adusumilli or Dr. Valerie Rusch likely will be the primary surgeon involved in the study. The Cancer Center is expecting 35 patients in the clinical trial and an estimated completion by November of 2022. Adusumilli is ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We d...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
An international research team has identified a novel molecular target with potential to significantly improve future treatment of malignant pleural mesothelioma. The recent findings could lead to a drug that targets key genetic inhibitors often preventing a patient’s own immune system from suppressing mesothelioma tumor growth. Dr. Antonio Giordano, part of the collaborative research team, said the goal is reducing mesothelioma mortality with a combinational therapy that includes this new target. “These findings help us define molecular mechanisms that may be key to mesothelioma aggressiveness and progression,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non–small-cell lung cancer and malignant pleural mesothelioma. As evidence for an exposure–response/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment. The purpose of this study was to develop a simple, sensitive, high-performance liquid chromatography method with UV detection for quantification of pemetrexed levels in human plasma. Method: The method involves a si...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Short Communication Source Type: research
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In this study, we comprehensively analyzed the expression profile and prognostic value of HOXC11 in human pan-cancer using online The Cancer Genome Atlas (TCGA) databases. HOXC11 was widely up-regulated in tumor tissues when compared with the normal tissues in pan-cancer across nine cancer types. In addition, high mRNA level of HOXC11 predicted poor overall survival (OS) of patients with adrenocortical carcinoma (ACC), colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), mesothelioma (MESO) and pancreatic adenocarcinoma (PAAD), respectively. By comparative analysis, we found that HOXC11 was up-regulated a...
Source: Life Sciences - Category: Biology Source Type: research
A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied, and poorly understood, group of patients that often is just written off,” surgical oncologist Dr. Michael Kluger at Columbia told The Mesothelioma Center at Asbestos.com. “But we’ve shown a meaningful survival.” Kluger,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion In our cohort, seafaring was associated with a higher overall incidence of cancer compared to the general population. While the majority of cancers could not be linked to specific occupational facto rs, increases in mesothelioma, lip and non-melanoma-skin cancer indicate previous exposure to asbestos, ultraviolet radiation and potentially also chemicals with dermal carcinogenic properties at sea.byUgelvig Petersen K, Pukkala E, Martinsen JI, Lynge E, Tryggvadottir L, Weiderpass E, Kj ærheim K, Heikkinen S, Hansen J. doi:10.5271/sjweh.3877
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Original article Source Type: research
Conclusion In our cohort, seafaring was associated with a higher overall incidence of cancer compared to the general population. While the majority of cancers could not be linked to specific occupational factors, increases in mesothelioma, lip and non-melanoma-skin cancer indicate previous exposure to asbestos, ultraviolet radiation and potentially also chemicals with dermal carcinogenic properties at sea. PMID: 31917456 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Authors: Tags: Scand J Work Environ Health Source Type: research
Abstract Two cases with diagnosis of mesothelioma were referred to our laboratories with a request for tissue burden analysis in order to determine the presence of ferruginous bodies and uncoated elongated mineral particles in tissue samples. The individuals shared in common a past background of working in tile manufacturing facilities where industrial talc was used in the production of the products. Both were found to have ferruginous bodies in their lung tissues as well as elongated talc fibers/ribbons and elevated numbers of noncommercial amphiboles in their tissues. To our knowledge, this is the first report o...
Source: Ultrastructural Pathology - Category: Pathology Authors: Tags: Ultrastruct Pathol Source Type: research
We present 2 cases of malignant peritoneal mesothelioma (MPM) characterized by a localized solid mass without ascites and showing 18F-FDG uptake. A 79-year-old man with a history of asbestos exposure suffered from an epithelioid MPM originating from the hepatoduodenal ligament with FDG uptake (SUVmax 16.8). Another 80-year-old man with esophageal cancer showed desmoplastic MPM of the small bowel mesentery with FDG uptake (SUVmax 4.0). Desmoplastic MPM is more aggressive and yields poorer prognosis compared with the epithelioid type. However, the present desmoplastic MPM case showed mild FDG uptake because of rich fibrosis.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Education | Environmental Health | Food and Drug Administration (FDA) | Genetics | Immunotherapy | Laboratory Medicine | Learning | Mesothelioma | Nutrition | Radiation Therapy | Study | Toxicology | Universities & Medical Training | Vaccines